Bevacizumab gamma for treating neovascular age-related macular degeneration

Bevacizumab gamma is in clinical development as an intravitreal injection (given through the white part of your eye known as vitreous) for the treatment of wet/neovascular age-related macular degeneration (nAMD). nAMD is a retinal condition that can cause deterioration of vision. nAMD can affect any part of your retina, a thin layer of tissue on the inside back wall of the eye. nAMD affects the middle of the vision in one or both eyes. The initial symptom of nAMD is usually blurred or distorted central vision. Other symptoms can include seeing straight lines as wavy, objects looking smaller than usual, changes in colour and hallucinations. If untreated, nAMD can progress to blindness. Other than off-label use, there are currently no licensed ophthalmic formulations of bevacizumab for the treatment of nAMD.